Company intelligence / Profile preview

Mitochon Pharmaceuticals

Radnor, Pennsylvania, United Statesmitochonpharma.com ↗

Ownership: Private
Development stage: Phase 1

Overview

MP101 has received orphan drug designation from the FDA for Huntington's disease and ALS. The EMA has approved a Phase I/IIa biomarker study for MP101 to treat patients with several neurodegenerative diseases. Preclinical studies showed MP101 preserves brain volume, neurons, and limb movement, and reduces seizure duration.

Therapeutic areas: NeurologyMetabolic Disorders
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

MP-101

Unknown

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Mitochon Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochon Pharmaceuticals.

Explore the full profile